NCT00286091View on ClinicalTrials.gov

Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

1,435

Participants

Timeline

Start Date

January 24, 2006

Primary Completion Date

July 30, 2010

Study Completion Date

April 9, 2014

Conditions
Hormone Refractory Prostate Cancer
Interventions
BIOLOGICAL

Denosumab

Administered by subcutaneous injection

BIOLOGICAL

Placebo

Same volume subcutaneous injection

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00286091 - Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer | Biotech Hunter | Biotech Hunter